Why the study?
Does a single low oral dose of pimobendan improve systolic and diastolic hemodynamics in patients with chronic congestive heart failure resulting from idiopathic cardiomyopathy?
Does a single low oral dose of pimobendan improve systolic and diastolic hemodynamics in patients with chronic congestive heart failure resulting from idiopathic cardiomyopathy?
A single low oral dose of pimobendan (2.5 mg) provides favorable short-term inotropic and lusitropic effects without increasing myocardial oxygen consumption in patients with heart failure due to idiopathic dilated cardiomyopathy.
Authors
No takes yet. Share an insight, caveat, or question.
Acute hemodynamic gains with pimobendan in dilated cardiomyopathy should not yet change practice; leaves open outcome benefits in randomized trials.
Ishiki et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: